New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:37 EDTGALTGalectin Therapeutics volatility elevated into results from fatty liver disease
Galectin Therapeutics April call option implied volatility is at 234, May is at 143, July is at 115; compared to its 26-week average of 101 according to Track Data, suggesting large near term price movement into reporting results from the first cohort of its Phase 1 clinical trial examining GR-MD-02 in fatty liver disease.
News For GALT From The Last 14 Days
Check below for free stories on GALT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 7, 2014
17:41 EDTGALTGalectin Therapeutics reports Q2 EPS (17c), consensus (21c)
"We continued to be encouraged by the progress in our development program. We announced on July 29, the results of the second cohort of patients in our Phase 1 clinical trial for patients with NASH with advanced fibrosis which demonstrated that double the dose of GR-MD-02 that was used in the first cohort was safe and well tolerated. We also have begun recruitment and enrollment of the third cohort of the Phase 1 clinical trial, that we expect will be concluded such that results may be presented in November 2014," said Peter G. Traber, M.D., CEO, President and Chief Medical Officer, Galectin Therapeutics. "This Phase 1 first-in-man study is evaluating the safety, tolerability, pharmacokinetics and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 when administered to patients with fatty liver disease with advanced fibrosis. Additionally, we recently announced that the first patient has been dosed in cohort 1 of a Phase 1B clinical trial evaluating GR-MD-02 in combination with ipilimumab (Yervoy(R)) in patients with metastatic melanoma. Preclinical data have shown that GR-MD-02 holds immense potential for increasing the effectiveness of other therapies and may be an important approach in enhancing cancer immunotherapy." At June 30, the company had $34.4M of non-restricted cash and cash equivalents which it believes will be sufficient to fund currently planned future operations, research and development through mid-2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use